SREBF1 and metabolic dysfunction-associated steatotic liver disease: Furthermore, insulin signalling in NAFLD leads to increased SREBP1c levels with reduced inhibitory feedback from other mechanisms as well, including AMPK‐mediated inhibition (Kohjima et al., 2008).